



Figure S1. cART regimen is not associated with differences in CHI3L1 and neutrophil count. **A.** CHI3L1 levels ($p=0.45$) and **B.** neutrophil counts ($p=0.78$) did not differ significantly between NRTI backbone combinations. AZT, zidovudine; ABC, abacavir; 3TC, lamivudine; TDF, tenofovir; FTC, emtricitabine. Other NRTI components of the cART regimen included: ABC+TDF+FTC ($n=1$); ABC+TDF+3TC ($n=1$); ABC+AZT ($n=2$); ABC ($n=2$); 3TC ($n=2$); AZT ($n=1$); no NRTI in cART regimen ($n=2$); and unknown ($n=5$). **C.** CHI3L1 levels ($p=0.27$) and **D.** neutrophil counts ($p=0.13$) did not differ significantly between cART regimen, according to core agent. NNRTI, non-nucleoside reverse transcriptase inhibitor, PI, protease inhibitor (includes ritonavir-boosted PIs); INSTI, integrase strand-transfer inhibitor.